-+ 0.00%
-+ 0.00%
-+ 0.00%
Knight Therapeutics submits MINJUVI Brazil filing to ANVISA for first-line DLBCL indication under Project Orbis
Share
Listen to the news
Knight Therapeutics submits MINJUVI Brazil filing to ANVISA for first-line DLBCL indication under Project Orbis
  • Knight Therapeutics filed a supplemental application with Brazil’s ANVISA to expand MINJUVI (tafasitamab) into first-line DLBCL or HGBL.
  • Submission seeks use with lenalidomide added to R-CHOP; review slated under Project Orbis.
  • Filing is backed by Phase 3 frontMIND data, aiming to move MINJUVI into earlier-line therapy in Brazil.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Knight Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608271800PRIMZONEFULLFEED9817453) on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending